

Anti-CD44 Antibody (Bivatuzumab Biosimilar)

Cat. No. AB502




Description	
Reactivities	Human/Cynomolgus
Target	CD44
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	50.61 kDa and 23.13 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 µM filtered
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage	
Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background	
CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression	

Assay Data


Bis-Tris PAGE



Bivatuzumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC


Assay Data



The purity of Bivatuzumab Biosimilar is greater than 95% as determined by SEC-HPLC.

ELISA Data

Bivatuzumab Biosimilar ELISA
0.1µg Human CD44, His Tag Per Well



Immobilized Human CD44, His Tag at 1µg/ml (100µl/well) on the plate. Dose response curve for Bivatuzumab Biosimilar with the EC50 of 5.2ng/ml determined by ELISA.